NR 602 WEEK 6 CHAPTER 5: ANATOMY OF THE BREAST

Chapter 5. The Breast Anatomy of the Female Breast The breasts are secondary reproductive glands of ectodermal origin. They are frequently referred to as modified sweat glands. Each breast lies on the superior aspect of the chest wall. In women, the breasts are the organs of lactation, whereas in men, the breasts are normally functionless and undeveloped. Histology The adult female breast contains glandular and ductal elements, stroma consisting of fibrous tissue that binds the individual lobes together and adipose tissue within and between the lobes. Each breast consists of 12–20 conical lobes. The base of each lobe is in close proximity to the ribs. The apex, which contains the major excretory duct of the lobe, is deep to the areola and nipple. In turn, each lobe consists of a group of lobules. The lobules have several lactiferous ducts, which unite to form a major duct that drains the lobes as they course toward the nipple–areolar complex. Approximately 80–85% of the normal breast is adipose tissue. The breast tissues are joined to the overlying skin and subcutaneous tissue by fibrous strands. In the nonpregnant, nonlactating breast, the alveoli are small and tightly packed. During pregnancy, the alveoli hypertrophy, and their lining cells proliferate in number. During lactation, the alveolar cells secrete proteins and lipids, which comprise breast milk. Histologic Changes in the Female Breast during the Life Span In response to multiglandular stimulation during puberty, the female breast starts to enlarge and eventually assumes its conical or spherical shape. Growth is the result of an increase in acinar tissue, ductal size and branching, and deposits of adipose, the main factor in breast enlargement. Also during puberty, the nipple and areola enlarge. Smooth muscle fibers surround the base of the nipple, and the nipple becomes more sensitive to touch. Once menses is established, the breast undergoes a periodic premenstrual phase during which the acinar cells increase in number and size, the ductal lumens widen, and breast size and turgor increase slightly. Many women have breast tenderness during this phase of the menstrual cycle. In response to progesterone during pregnancy, breast size and turgidity increase considerably. These changes are accompanied by deepening pigmentation of the nipple–areolar complex, nipple enlargement, areolar widening, and an increase in the number and size of the lubricating glands in the areola. The breast ductal system branches markedly, and the individual ducts widen. With cessation of nursing or administration of estrogens, which inhibit lactation, the breast rapidly returns to its prepregnancy state, with marked diminution of cellular elements and an increase in adipose deposits. Following menopause, which typically occurs during the fifth decade of life, the breast undergoes a gradual process of atrophy and involution. There is a decrease in the number and size of acinar and ductal elements, so that the breast tissue regresses to an almost infantile state. Adipose tissue may or may not atrophy, with disappearance of the parenchymal elements. The adult female breast mound characteristically forms a near hemispheric contour on each side of the chest wall, usually extending from just below the level of the second rib inferiorly to the sixth or seventh rib. The breast mound is usually situated between the lateral sternal border and the anterior axillary fold. The breast tissue extends over a larger anatomic area than the more obvious breast mound. The superior portion of the breast tissue emerges gradually from the chest wall inferior to the clavicle, whereas the lateral and inferior borders are better defined. The Nipple & Areola The areola is a circular pigmented zone 2–6 cm in diameter at the tip of the breast. Its color varies from pale pink to deep brown depending on age, parity, and skin pigmentation. The skin of the areola contains multiple small, elevated nodules beneath which are located the sebaceous glands of Montgomery. The glands are responsible for lubrication of the nipple and help prevent cracks and fissures in the nipple–areolar complex that occur during breastfeeding. During the third trimester of pregnancy, the sebaceous glands of Montgomery markedly hypertrophy. Blood Vessels, Lymphatics, & Nerves The breast has a rich blood supply with multiple arteries and veins. Perforating branches from the internal thoracic/mammary artery that penetrate the second to the fifth intercostal interspaces supply blood to the medial half of the breast. These arteries perforate the intercostal muscles and the anterior intercostal membrane to supply both the breast and the pectoralis major and minor muscles. During pregnancy, and not infrequently in advanced breast disease, the intercostal perforators may enlarge from engorgement. Veins Venous return from the breast closely follows the routes of the arterial system. Blood returns to the superior vena cava via the axillary and internal thoracic veins. It also returns via the vertebral venous plexuses, which are fed by the intercostal and azygos veins. Through the azygos veins, there is also some minor flow into the portal system. A rich anastomotic plexus of superficial breast veins is located in the subareolar region. Lymphatics of the breast and axilla. A thorough knowledge of the lymphatic drainage of the breast is of critical importance to the clinician. This is true because the lymphatic drainage has significant implications in several disease etiologies, including breast cancer. To a large extent, modern, less invasive surgical management techniques such as sentinel lymph node biopsy are based on a solid understanding of the pattern of lymphatic drainage in the breast. Lymphatic drainage in the breast may be divided into 2 main categories: superficial (including cutaneous) drainage and deep parenchymatous drainage. SUPERFICIAL DRAINAGE A large lymphatic plexus exists in the subcutaneous tissues of the breast deep to the nipple–areolar complex. This plexus drains the areola and nipple regions, including the cutaneous and subcutaneous tissues adjacent to the nipple–areolar complex. In addition, the superficial plexus drains the deep central parenchymatous region of the breast. DEEP PARENCHYMATOUS DRAINAGE The deep parenchymatous lymph vessels drain the remainder of the breast as well as some portion of the skin and subcutaneous tissues of the nipple–areolar complex not served by the superficial plexus. Small periductal and periacinal lymph vessels collect parenchymal lymph and deliver it to the larger interlobar lymphatics. The majority of lymphatic drainage from both the retroareolar and the deep interlobar lymphatics of the breast travel to the ipsilateral axillary lymph nodes. The route of drainage to the highest axillary node or nodes is not reproducible from patient to patient. In general, however, the drainage of the breast is to the anterior axillary or subpectoral nodes, which are located deep to the lateral border of the pectoralis major muscle, close to the lateral thoracic artery. Surgeons usually classify the axillary lymph nodes in levels according to their relationship with the pectoralis minor muscle. Thus, lymph nodes located lateral or below the pectoralis minor muscle are classified as level I lymph nodes. Lymph nodes located deep to the pectoralis minor muscle constitute level II lymph nodes. Nerves Encountered during Axillary Dissection The lateral and anterior cutaneous branches of T4–6 supply the cutaneous tissues covering the breasts. Two major nerves and 2 smaller groups of nerves are in close proximity to the breast area and thus assume importance in breast surgery: 1. The thoracodorsal nerve, a branch of the posterior cord of the brachial plexus (C5–7), runs inferiorly along with the subscapular artery lying close to the posterior axillary wall and the ventral surface of the subscapular muscle. 2. The long thoracic nerve (nerve of Bell) arises from the anterior primary divisions of C5–7 at the level of the lower half of the anterior scalene muscle. In the neck, the nerve descends dorsal to the trunks of the brachial plexus on the inferior segment of the middle scalene muscle. Further descent places it dorsal to the clavicle and the axillary vessels. 1. The intercostal brachial nerves are 3 relatively minor cutaneous nerves that supply the skin of the medial surface of the upper arm. They transverse the lateral chest wall to the upper inner surface of the arm, passing across the base of the axilla. 2. The medial and lateral pectoral nerves supply the 2 pectoral muscles and pass from the axilla to the lateral chest wall. The lateral pectoral nerve, which arises from the lateral cord of the plexus, pierces the clavipectoral fascia membrane together with the thoracoacromial artery and supplies the pectoralis major muscle. Diseases of the Breast Fibrocystic Breast Changes Essentials of Diagnosis • Painful, often multiple, usually bilateral mobile masses in the breast. • Rapid fluctuation in the size of the masses is common. • Frequently, pain occurs or increases, as does size during the premenstrual phase of the cycle. • Most common age is 30–50 years; occurrence is rare in postmenopausal women. Pathogenesis Fibrocystic breast changes, formerly known as fibrocystic disease, chronic cystic mastitis, or mammary dysplasia, are the most common cause of cyclic breast pain or mastalgia in reproductive age women. The term is imprecise and encompasses a wide spectrum of pathologic entities. Clinical Findings Fibrocystic changes are common and affect more than 50% of women of reproductive age. These changes are thought to be the result of a hormonal imbalance that may produce asymptomatic breast lumps that are discovered by palpation. Cyclical breast pain or tenderness is often the presenting symptom and calls attention to the mass. The pain is caused by the proliferation of normal glandular breast tissue with estrogen stimulating the ductal elements and progesterone stimulating the stroma. There may be nonbloody, green or brown discharge from the nipple. In many cases, discomfort occurs or is increased during the premenstrual phase of the cycle. Fluctuations in size and rapid appearance or disappearance of a breast mass are common in cystic changes. In many women, caffeine seems to potentiate these symptoms. However, the role of caffeine as a direct cause of these symptoms has never been proven. Pain, fluctuation in size, and multiplicity of lesions are the features most helpful in differentiation from carcinoma. Differential Diagnosis Pain, fluctuation in size, and multiplicity of lesions help to differentiate these lesions from carcinoma and the benign entity of fibroadenoma. Final diagnosis often rests on biopsy and pathologic determination. Ultrasonography may be helpful in the diagnosis; mammography is usually not indicated for women under the age of 30 as the breast tissue in these young women may be too radiodense to allow a meaningful evaluation. Aspiration and/or sonography may be useful in differentiating a cystic from a solid mass. Treatment Once a benign diagnosis or normal findings have been established by biopsy or on clinical or imaging findings, simple reassurance will provide many patients with adequate relief. For those patients who still seek treatment, symptomatic relief by avoiding trauma and by wearing a bra with adequate support can be very helpful. The role of caffeine consumption in the development and treatment of fibrocystic change has never been proven; however, many patients report relief of symptoms after abstinence from coffee, tea, and chocolate. Similarly, observational studies have suggested that low-fat diets can provide some relief. The data regarding the utility of vitamin E supplementation and evening primrose oil are controversial. Mild analgesics such as acetaminophen and nonsteroidal anti-inflammatory drugs (NSAIDs) can be used to relieve breast pain. For more symptomatic women, danazol and tamoxifen have been found to be effective, although their significant side effects have limited their acceptability and utility. Prognosis Exacerbations of pain, tenderness, and cyst formation may occur at any time until menopause, when symptoms subside. Patients should be reassured that single nonproliferative lesions like fibrocystic changes are not associated with an increased risk of breast cancer. On the other hand, the presence of multiple nonproliferative lesions or proliferative lesions (florid hyperplasia, sclerosing adenosis, and intraductal papillomas), particularly those with atypia (atypical lobular or ductal hyperplasia), is associated with an increased risk of subsequent breast cancer. Fibroadenoma of the Breast Pathogenesis This common, benign neoplasm occurs most frequently in young women, usually within 20 years after puberty. It is somewhat more frequent and tends to occur at an earlier age in black women than in white women. The etiology of fibroadenomas is not known, but a hormonal relationship is likely since they can increase in size during pregnancy or with estrogen therapy and usually regress after menopause. Multiple tumors in 1 or both breasts are found in 10–15% of patients. Clinical Findings The typical fibroadenoma is a round, firm, discrete, relatively movable, nontender mass 1–5 cm in diameter. The tumor is usually discovered accidentally. Clinical diagnosis in young patients is generally not difficult. Fibroadenomas typically present as well-defined solid masses with benign imaging features on ultrasound and can be managed with core needle biopsy or short-term (3–6 months) follow-up with a repeat ultrasound and breast examination. Differential Diagnosis Definitive diagnosis can only be confirmed with a core biopsy or excision if the patient is symptomatic or wishes the mass to be excised. Cryoablation is an alternative to surgical excision of fibroadenomas, but should only be considered after a core biopsy diagnosis of fibroadenoma has been made. Rapid growth sometimes raises the suspicion for a phyllodes tumor and can mandate an excision to confirm the diagnosis and rule out a malignancy. Simple fibroadenomas do not raise the subsequent risk of breast cancer, although the presence of adjacent proliferative changes or a complex fibroadenoma is associated with a slightly increased risk. Phyllodes tumors of the breast (previously called cystosarcoma phyllodes) are fibroepithelial tumors that tend to grow rapidly and may sometimes be confused with benign fibroadenomas. This tumor may reach a large size and, if inadequately excised, will recur locally. The lesion can be, but rarely is, malignant. Treatment Treatment is by local excision of the mass with a margin of surrounding normal breast tissue. The treatment of malignant phyllodes tumors is more controversial but generally involves wide local excision with appropriate margins. The role of radiation and chemotherapy is controversial. Breast conservation even for large tumors may not compromise cancer-specific survival. Nipple Discharge Pathogenesis Nipple discharge is usually characterized as normal lactation, galactorrhea or benign physiologic nipple discharge, and pathologic nipple discharge. The most common causes of pathologic nipple discharge are intraductal papillomas and, less frequently, carcinoma and fibrocystic change with ectasia of the ducts. The discharge is usually unilateral, emanating from a single duct, and can be serous, bloody, or serosanguineous. Clinical Findings The important characteristics of the discharge and some other factors to be evaluated by history and physical examination are as follows: 1. Nature of discharge (serous, bloody, or other) 2. Association with or without a mass 3. Unilateral or bilateral 4. Single duct or multiple duct discharge 5. Discharge that is spontaneous, persistent or intermittent, or must be expressed 6. Discharge produced by pressure at a single site or by general pressure on the breast 7. Relation to menses 8. Premenopausal or postmenopausal 9. History of oral contraceptive use or estrogen replacement for postmenopausal symptoms Differential Diagnosis Galactorrhea or physiologic nipple discharge is frequently the result of hyperprolactinemia secondary to medications such as phenothiazines, endocrine tumors such as lactotroph adenomas, or endocrine abnormalities such as hypothyroidism and pituitary or hypothalamic disease (Table 5–1). Galactorrhea usually manifests as bilateral multiductal milky nipple discharge in the nonlactating breast. If the physical examination is otherwise normal, imaging is negative, and the discharge is multiductal and nonbloody, a pregnancy test, prolactin levels, renal and thyroid function tests, and appropriate endocrinologic follow-up may be necessary with appropriate treatment of the underlying cause. Table 5–1. Causes of Galactorrhea. Idiopathic Drug inducedPhenothiazines, butyrophenones, reserpine, methyldopa, imipramine, amphetamine, metoclopramide, sulpiride, pimozide, oral contraceptive agents Central nervous system (CNS) lesions Pituitary adenoma, empty sella, hypothalamic tumor, head trauma Medical conditions Chronic renal failure, sarcoidosis, Schüller-Christian disease Cushing's disease, hepatic cirrhosis, hypothyroidism Chest wall lesions Thoracotomy, herpes zoster Pathologic nipple discharge is usually unilateral, spontaneous serous or serosanguineous from a single duct and is usually caused by an intraductal papilloma or, more infrequently, by an intraductal malignancy. In either case, a palpable mass may not be present. The involved duct may be identified by pressure at different sites around the nipple at the margin of the areola. Bloody discharge is more suggestive of cancer but is usually caused by a benign papilloma in the duct. Treatment In any case, surgical excision of the involved duct should be performed once the workup has ruled out additional breast findings that need to be addressed. Purulent discharge can originate in a subareolar abscess and may require excision of the abscess and related lactiferous sinus. Fat Necrosis Fat necrosis is a benign condition of the breast but is of clinical importance because it produces a mass, often accompanied by skin or nipple retraction, that is clinically indistinguishable from carcinoma. Trauma and surgery are the presumed etiology, although only about half of patients recall a history of injury to the breast. Ecchymosis is occasionally observed in conjunction with the mass. Tenderness may or may not be present. If untreated, the mass associated with fat necrosis gradually disappears. Should the mass not resolve after several weeks, a biopsy should be considered. Once the diagnosis is established, surgical excision is usually not necessary. Breast Abscess During lactation and nursing, an area of redness, tenderness, and induration may develop in the breast. In its early stages, the infection can often be resolved while continuing nursing with the affected breast and administering an antibiotic. If the lesion progresses to form a palpable mass with local and systemic signs of infection, an abscess has developed and needs to be drained. Even in this setting breastfeeding or pumping can help in controlling the pain and discomfort associated with the infection as well as shorten the duration of the infection. Less frequently, a subareolar abscess may develop in young or middle-age women who are not lactating. These infections tend to recur after simple incision and drainage unless the area is explored in a quiescent interval with excision of the involved lactiferous duct or ducts at the base of the nipple. Except for the subareolar type of abscess, infection in the breast is very rare unless the patient is lactating. If a patient with a suspected breast infection does not respond to treatment, inflammatory breast cancer should be suspected especially when associated with axillary lymphadenopathy. Malformation of the Breast Many women consult their physicians for abnormalities in either the size or the symmetry of their breasts. Difference in size between the 2 breasts is common. If extreme, however, these differences may be corrected by cosmetic surgery, although the breast tissue in these individuals is otherwise normal. Similarly, woman may complain of overly large breasts (macromastia). Studies fail to show any endocrinologic or pathologic abnormalities, and these patients may also be considered candidates for cosmetic surgery such as breast-reduction mammoplasty. Less common malformations of the breast include amastia, complete absence of 1 or both breasts, or the presence of accessory nipples (polythelia) and breast tissue (polymastia) along the embryologic milk line, which occurs in 1–2% of whites. Carcinoma of the Female Breast Essentials of Diagnosis • Early findings: Single, nontender, firm to hard mass with ill-defined margins; mammographic abnormalities and no palpable mass. • Later findings: Skin or nipple retraction; axillary lymphadenopathy; breast enlargement, redness, edema, brawny induration, peau d'orange, pain, fixation of mass to skin or chest wall. • Late findings: Ulceration; supraclavicular lymphadenopathy; edema of arm; bone, lung, liver, brain, or other distant metastases. General Considerations Cancer of the breast is the most common cancer in women, excluding nonmelanoma skin cancers. After lung cancer, it is the second most common cause of cancer death for women. The American Cancer Society estimates that over 210,000 new cases of cancer of the breast will be diagnosed in 2010, resulting in over 40,000 deaths. These figures include male breast cancer, which accounts for less than 1% of annual breast cancer incidence. At the present rate of incidence, a woman's risk of developing invasive breast cancer in her lifetime from birth to death is 1 in 8. This figure is from the Surveillance, Epidemiology, and End Results Program (SEER) of the National Cancer Institute (NCI) and is often cited but needs clarification. The data include all age groups in 5-year intervals with an open-ended interval at 85 years and above. In the United States, breast cancer is the most common cancer among women of all ethnic groups, although the incidence of the disease is highest among white patients. In general, rates reported from developing countries are lower than those reported from developed countries, with the notable exception of Japan. Women with a family history of breast cancer are more likely to develop the disease than controls. The risk of being diagnosed with breast cancer for a patient with 1 affected first-degree relative (mother or sister) is increased by almost 2-fold. With 2 affected first-degree relatives, the increased risk is almost 3-fold. The risk is even higher if those relatives were diagnosed at a young age. A family history of breast cancer is, however, only reported by 15–20% of patients with breast cancer. Inherited specific genetic mutations that predispose patients to breast cancer such as, BRCA1 and BRCA2 gene mutations, are rare, accounting for approximately 5% of all breast cancers. BRCA mutations place affected women at a significantly increased lifetime risk, up to a 70%, of being diagnosed with breast cancer. Nulliparous women and women whose first full-term pregnancy was after age 30 years have a slightly higher incidence of breast cancer than multiparous women. Late menarche and artificial menopause are associated with a lower incidence of breast cancer, whereas early menarche (before age 12 years) and late natural menopause (after age 50 years) are associated with a slight increase in risk of developing breast cancer. Fibrocystic changes of the breast and other nonproliferative breast lesions are not associated with an increased risk of breast cancer. However, the presence of multiple nonproliferative lesions and the presence of proliferative changes, especially those associated with cytologic atypia, are associated with an increased incidence of cancer. Correspondingly, a personal history of breast cancer is the greatest risk factor for subsequent breast cancer events. Women who are at greater-than-normal risk of developing breast cancer should be identified by their physicians and followed carefully. Screening programs involve periodic physical examination and screening mammography; screening magnetic resonance imaging of the breasts for those asymptomatic patients at highest risk may increase the detection rate of breast cancer and may improve the survival rate, although this has not yet been demonstrated. Unfortunately, more than 50% of women who develop breast cancer do not have significant identifiable risk factors. Staging The physical examination of the breast and additional preoperative studies are used to determine the clinical stage of a breast cancer. Clinical staging is based on the TNM (tumor, node, metastasis) system of the International Union Against Cancer. This classification considers tumor size, clinical assessment of axillary nodes, and the presence or absence of distant metastases. The assessment of the clinical stage is important in planning therapy. Histologic (or pathologic) staging is determined following surgery and along with clinical staging helps determine prognosis. Clinical Findings The majority of patients with breast cancer are diagnosed as a result of an abnormal mammogram and less often because of a palpable mass. The initial evaluation should include assessment of the local lesion, including a bilateral mammogram, if not previously performed, and breast ultrasound as indicated. The initial workup should include laboratory tests such as a complete blood count, liver function tests, and alkaline phosphatase. The search for distant spread should only be reserved for locally advanced breast cancers or if signs/symptoms of distant spread are present. Symptoms When the history is taken, special note should be made of the onset and duration of menarche, pregnancies, parity, artificial or natural menopause, date of last menstrual period, previous breast lesions and/or biopsies, hormonal supplementation, radiation exposure, and a family history of breast cancer. Back or other bone pain may be the result of osseous metastases. Systemic complaints or weight loss should raise the question of metastases, which may involve any organ but most frequently involve the bones, liver, and lungs. The more advanced the cancer in terms of aggressive histologic features, size of primary lesion, local invasion, and extent of regional node involvement, the higher is the incidence of metastatic spread to distant sites. Lymph node involvement is the single most significant prognostic feature and increases with increasing tumor size and aggressive histologic features such as pathologic grade. Most patients with palpable breast cancers present with painless masses in the breast, most of which are discovered by the patient herself. Less frequent symptoms are breast pain; nipple discharge; erosion, retraction, enlargement, or itching of the nipple; and redness, generalized hardness, enlargement, or shrinking of the breast. Rarely, an axillary mass, swelling of the arm, or bone pain (from metastases) may be the first symptoms. Because of organized screening programs, fewer than 10% of breast cancers are detected solely on physical examination, and more than 90% are detected as a result of an abnormal mammogram Signs Inspection of the breast is the first step in physical examination and should be carried out with the patient sitting, arms at sides and then overhead. Abnormal variations in breast size and contour, minimal nipple retraction, and slight edema, redness, or retraction of the skin can be identified. Asymmetry of the breasts and retraction or dimpling of the skin can often be accentuated by having the patient raise her arms overhead or press her hands on her hips in order to contract the pectoralis muscles. Axillary and supraclavicular areas should be thoroughly palpated for enlarged nodes with the patient sitting (Fig. 5–4). Palpation of the breast for masses or other changes should be performed with the patient both seated and supine with the arm abducted (Fig. 5–5). Breast cancer usually consists of a nontender, firm or hard lump with poorly delineated margins generally caused by local infiltration. Slight skin or nipple retraction is an important sign as it may affect staging. Minimal asymmetry of the breast may be noted. Very small (1–2-mm) erosions of the nipple epithelium may be the only manifestation of Paget's carcinoma. Watery, serous, or bloody discharge from the nipple is an occasional early sign but is more often associated with benign disease, as discussed earlier. A lesion smaller than 1 cm in diameter may be difficult or impossible for a clinical examiner to feel and yet may be discovered by the patient's self-examination. During the premenstrual phase of the cycle, increased innocuous nodularity may suggest neoplasm or may obscure an underlying lesion. If there is any question regarding the nature of an abnormality under these circumstances, the patient should be asked to return after her period. The following are characteristic of advanced carcinoma: edema, redness, nodularity, or ulceration of the skin; the presence of a large primary tumor (>5 cm); fixation to the chest wall; enlargement, shrinkage, or retraction of the breast; marked axillary lymphadenopathy; edema of the ipsilateral arm; supraclavicular lymphadenopathy; and distant metastases. Most frequently, metastases initially tend to involve regional lymph nodes first, which may be clinically palpable, before spreading to distant sites. The axillary lymph nodes receive more than 85% of the lymphatic drainage from the breast. One or 2 movable, nontender, not particularly firm axillary lymph nodes 5 mm or less in diameter are frequently present and are generally of no clinical significance. Any firm or hard nodes larger than 5 mm in diameter are highly suspicious for nodal metastases. Axillary nodes that are matted or fixed to skin or deep structures indicate locally advanced disease (at least stage III). Usually no nodes are palpable in the supraclavicular fossa. Firm or hard nodes of any size in this location or just beneath the clavicle (infraclavicular nodes) are indicative of locally advanced disease and suggest the strong possibility of distant metastatic sites of cancer. Biopsy or fine-needle aspiration to confirm nodal involvement in these areas is paramount. Ipsilateral supraclavicular nodes containing cancer indicate that the patient is in an advanced stage of the disease (stage IIIC). Edema of the ipsilateral arm, commonly caused by metastatic infiltration of regional lymphatics, is also a sign of advanced cancer. Special Clinical Forms of Breast Carcinoma PAGET'S DISEASE OF THE BREAST Paget's disease of the breast refers to the eczematoid eruption and ulceration that arises from the nipple, can spread to the areola, and is associated with an underlying carcinoma. An underlying mass is palpable in about 50% of patients with Paget's disease. Of these masses, 95% are found to be an invasive cancer, mostly infiltrating ductal. For patients with Paget's disease and no underlying palpable mass, a noninvasive breast cancer or ductal carcinoma in situ is found in 75% of cases. Pain, itching, and/or burning are often the presenting symptoms, along with a superficial erosion or ulceration. Less frequently, a bloody discharge and nipple retraction are observed. The diagnosis is established most often by full-thickness biopsy of the lesion, which reveals the pathognomonic intraepithelial adenocarcinoma cells or Paget cells within the epidermis of the nipple. Paget's disease is uncommon, accounting for approximately 1% of all breast cancers. It is frequently misdiagnosed and treated as dermatitis or bacterial infection, leading to an unfortunate delay in detection. Mastectomy has traditionally been the mainstay of therapy, although breast conservation followed by whole breast radiation can be attempted if nipple, areola, and wide local excision of the palpable mass or area of mammographic abnormality can be performed with an acceptable cosmetic result and negative margins. INFLAMMATORY CARCINOMA Inflammatory carcinoma is an aggressive form of breast cancer that is characterized by diffuse, brawny edema of the skin of the breast with an erysipeloid border, usually without an underlying palpable mass. Generally, this is a clinical diagnosis with pathologic confirmation of tumor embolization in the dermal lymphatics by biopsy of the overlying skin and should not be confused with noninflammatory locally advanced breast cancer. Inflammatory breast cancer is an aggressive but rare form of breast cancer representing less than 5% of cases. At presentation, nearly 35% of patients with inflammatory breast cancer have evidence of metastases. The inflammatory component, often mistaken for an infectious process, is caused by the blockage of dermal lymphatics by tumor emboli, which results in lymphedema and hyperemia. If a suspected skin infection does not rapidly respond (1–2 weeks) to a course of antibiotics, biopsy must be performed. Treatment usually consists of several cycles of neoadjuvant chemotherapy followed by surgery and/or radiotherapy depending on tumor response. A modified radical mastectomy is usually recommended for locoregional control as long as a complete resection of the tumor can be accomplished. OCCURRENCE DURING PREGNANCY OR LACTATION Pregnancy-associated breast cancer is defined as breast cancer that is diagnosed during pregnancy, in the first postpartum year, or anytime during lactation. The frequency of breast cancer during pregnancy or lactation ranges between 1:3000 and 1:10,000. The association of pregnancy and breast cancer presents a diagnostic and therapeutic dilemma for the patient and the physician. Women with breast cancer diagnosed during pregnancy or lactation tend to present at a later stage due in part to diagnostic delays. In the past, pregnancy-associated breast cancer was thought to lead to a worse outcome for the patient. More recent studies, however, have reported similar outcomes for women with breast cancer diagnosed during pregnancy and lactation when compared with nonpregnant breast cancer patients after controlling for stage, age, and other prognostic factors. Termination of the pregnancy, formerly performed routinely in the first two trimesters, has not been demonstrated to improve outcome. In most instances, modified radical mastectomy in pregnancy is the minimal treatment of choice, with the possible exception of the latter part of the third trimester, wherein breast-conservation therapy followed by postpartum radiotherapy may be considered. BILATERAL BREAST CANCER Clinically evident simultaneous bilateral breast cancer occurs in less than 1% of cases, but there is a 5–8% incidence of later occurrence of cancer in the second breast. Bilaterality occurs more often in women younger than age 50 years and is more frequently associated with a lobular carcinoma and in patients with hereditary breast cancer syndromes such as Li-Fraumeni syndrome. The incidence of second breast cancers increases directly with the length of time the patient is alive after her first cancer and is approximately 1.0% per year and is significantly higher in patients with hereditary breast cancer syndromes. In patients with breast cancer, careful screening of the contralateral breast at the time of initial diagnosis and at regular intervals thereafter is warranted. Routine biopsy of the opposite breast is usually not indicated. Mammography Mammography is the breast imaging modality of choice and the only screening method that has been consistently found to decrease mortality of breast cancer. Some breast cancers can be identified by mammography as early as 2 years before reaching a size detectable by palpation. Although false-positive and false-negative results are occasionally obtained with mammography, the experienced radiologist can interpret mammograms correctly in approximately 90% of cases. Ultrasound and magnetic resonance imaging (MRI) are not recommended for screening the general population, and their primary role is as adjuncts to an abnormal mammogram. Because up to 15% of cancers that are detected on clinical exams are not seen on mammograms, a negative mammogram should preclude further intervention in patients with a dominant or suspicious mass. The use of a targeted ultrasound can help decrease the false-negative rate of mammograms and evaluate the mammographically occult palpable breast mass. Cytology Cytologic examination of nipple discharge or cyst fluid may be helpful on rare occasions. As a rule, mammography and breast biopsy are required when nipple discharge or cyst fluid is bloody or cytologically equivocal. Biopsy The diagnosis of breast cancer depends ultimately on examination of tissue removed by biopsy. Treatment should never be undertaken without an unequivocal histologic diagnosis of cancer. The safest course is biopsy examination of all suspicious masses found on physical examination and, in the absence of a mass, of suspicious lesions demonstrated by mammography. The simplest method is by fine-needle aspiration (FNA). This method is, however, limited by its inability to distinguish invasive from noninvasive breast cancers and the relatively high rate of nondiagnostic studies, especially for nonpalpable abnormalities and with less experienced practitioners. In many centers, core needle biopsies, most often with image guidance, have replaced open surgical biopsies. Core needle biopsies offer the advantage of a more definitive histologic diagnosis, minimize the risk of inadequate samples, and allow the distinction between invasive and noninvasive breast cancers. Open surgical biopsies, often with wire localization, should be reserved for those lesions that are technically unattainable with core needle biopsies or in the event of core needle biopsy results that do not correlate with the imaging findings (discordant results). In general, outpatient biopsy followed by definitive surgery at a later date gives patients time to adjust to the diagnosis of cancer, meet with members of the multidisciplinary team involved with managing breast cancer, and consider a second opinion as well as alternative forms of treatment. Studies show no adverse effects from the short (1–2 weeks) delay of the 2-step procedure, and this is the current recommendation of the NCI. At the time of the initial biopsy of breast cancer, the specimen can also be analyzed with immunohistochemical staining for hormone and growth factor (eg, HER-2-Neu) receptors. Tumor analysis using reverse transcriptase polymerase chain reaction (RT-PCR) technology from pathologic specimens to assess the tumor recurrence risk is now available. Laboratory Findings A complete blood cell count (CBC), chemistry panel including liver function tests (LFTs), and a β-human chorionic gonadotropin (β-hCG) in premenopausal patients should be obtained as part of the initial evaluation. An elevation in alkaline phosphatase or liver function may be an indication of distant metastatic disease and warrants further investigation. Hypercalcemia may be seen in advanced cases of metastatic cancer. Imaging Studies Most systematic reviews have concluded that the routine radiologic evaluation for metastatic disease is unnecessary in the majority of patients since the overall yield is low. In general, the prevalence of metastatic disease increases with the clinical stage of the disease. The Cancer Care Ontario Practice Guidelines Initiative recommends against routine staging for clinical stage I disease, whereas they recommend routine staging in patients with stage III disease and radionuclide bone scanning in patients with stage II disease. The imaging modality of choice has not been standardized, although computed tomography (CT) scanning of chest, abdomen, and pelvis offers a more sensitive and attractive 1-visit option at the price of a higher risk of false-positive results, cost, and radiation exposure. In addition, evaluation for skeletal metastases with radionuclide bone scans would still be required. The combination of positron emission tomography (PET) and CT scans is a promising tool in the staging and metastatic evaluation of breast cancer because it allows for the evaluation of visceral and bony metastases. However, data regarding its routine use in the metastatic workup of patients with breast cancer are lacking. The American Society of Clinical Oncology has found that there is insufficient evidence to support the routine use of tumor markers such as CA 15-3, CA 27.29, and carcinoembryonic antigen (CEA). In general, assessment of myocardial function should be reserved for patients at high risk of cardiotoxicity (age >65 years or underlying heart disease) prior to initiating treatment with anthracyclines and in all patients scheduled to receive trastuzumab. Early Detection Screening Programs Mammography remains the single best screening procedure for the early detection of breast cancer. The majority of breast cancers in the United States are detected as a result of an abnormal screening study. In general, depending on a woman's age and the density of her breasts, the sensitivity of mammography is 70–90%, and its specificity is greater than 90%. Yearly mammogram screening among women continues to increase, so that in 1997, roughly 85% of women had had a mammogram at least once previously. Despite a consensus on the importance of mammographic screening, mammography has still not been demonstrated unequivocally to decrease breast cancer mortality across all age groups. In women between 50 and 69 years of age, there is reasonable evidence, based largely on 8 randomized controlled trials, that screening mammography is beneficial. In elderly patients over the age of 70 years, however, the optimal frequency of screening is still unknown because they have not generally been included in most large cooperative screening trials and because of their limited life expectancy, which can affect gains in breast mortality. For younger women, the evidence is also not entirely clear. For women age 40–49 years, there appears to be a small benefit, which comes at the price of a higher number of patients in that age group who need to be screened. Current screening recommendations from the American College of Radiology, the American Cancer Society, and the American Medical Association call for annual mammograms starting at age 40 years. The American College of Obstetricians and Gynecologists calls for screening mammography every 1–2 years for women age 40–49 and annually thereafter. There is no recommendation for a “baseline” examination prior to age 40 years, nor is there any evidence to support this practice in women younger than this age. Women with a genetic predisposition to breast cancer should be screened using a combination of screening mammography and MRI beginning at age 25 or based on the age of earliest onset breast cancer in the family. Breast Examination Even though several randomized controlled trials included clinical breast examination with mammography, the utility of clinical breast exams remains debatable. From these studies, it appears that mammography detected approximately 90% of breast cancers and clinical breast exams detected approximately 50% with significant but not total overlap. A recent review of the literature concluded that the effectiveness of clinical breast examination has yet to be proven. The few randomized controlled trials that have examined breast self-examination have similarly failed to show a benefit in the rates of breast cancer diagnosis and mortality, suggesting that breast self-examination only be offered as an adjunct to regular screening and patients be educated about its limitations. Genetic Testing A positive family history of breast cancer is recognized as a risk factor for the subsequent development of breast cancer. With the discovery of 2 major breast cancer predisposition genes, BRCA1 (17q21) and BRCA2 (13q12-13), there has been increasing interest in genetic testing. Mutations in these 2 genes are associated with an elevated risk for breast cancer, as well as ovarian, colon, prostate, and pancreatic cancers. Of all women with breast cancer, approximately 5–10% may have mutations in BRCA1 or BRCA2. The estimated risk of a patient developing cancer with a BRCA1 or BRCA2 mutation is believed to be between 40% and 85%. Particular mutations may be more common in specific ethnic groups like the Ashkenazi Jewish population. Table 5–2. Recommendations from the Us Preventive Services Task Force on WHO Should Be Offered Genetic Testing for Brca Mutations. For non-Ashkenazi Jewish women: Two first-degree relatives with breast cancer, 1 of whom was diagnosed at age 50 or younger A combination of 3 or more first- or second-degree relatives with breast cancer regardless of age at diagnosis A combination of both breast and ovarian cancer among first- and second-degree relatives A first-degree relative with bilateral breast cancer A combination of 2 or more first- or second-degree relatives with ovarian cancer, regardless of age at diagnosis A first- or second-degree relative with both breast and ovarian cancer at any age History of breast cancer in a male relative For women of Ashkenazi Jewish descent: Any first-degree relative (or 2 second-degree relatives on the same side of the family) with breast or ovarian cancer Pathologic Types Numerous pathologic subtypes of breast cancer can be identified histologically (Table 5–3). More than 95% of breast malignancies arise from the epithelial elements of the breast. These pathologic types are distinguished by the histologic appearance and growth pattern of the tumor. In general, breast cancer arises either from the epithelial lining of the large or intermediate-sized ducts (ductal) or from the epithelium of the terminal ducts of the lobules (lobular). The histologic subtypes have only slight bearing on prognosis when outcomes are compared after accurate staging. Colloid (mucinous), medullary, papillary, adenoid cystic, and tubular histologies are generally believed to have a more favorable prognosis. Other histologic criteria have been studied in an attempt to substratify patients based on features such as tumor differentiation, lymphovascular space invasion, and tumor necrosis. The noninvasive cancers by definition lack the ability to spread. However, in patients whose biopsies show noninvasive intraductal cancer, associated invasive ductal cancers are present in 1–3% of cases. Lobular carcinoma in situ is considered by some to be a premalignant lesion that by itself is not a true cancer. Hormone Receptor Sites The presence or absence of estrogen and/or progesterone receptors in the nucleus of tumor cells is of critical importance in managing patients with initial, recurrent, and metastatic disease. Both estrogen receptors (ERs) and progesterone receptors (PRs) are nuclear hormone receptors. After binding their respective hormones in the cytoplasm of the target cell, the DNA-binding sites on the receptor are unmasked, and the activated complex migrates into the nucleus in order to bind to their respective hormone-responsive DNA elements. ERs may be of prognostic significance, but current evidence is still unclear. For small node-negative tumors, the presence of ER is associated with lower likelihood of recurrence at 5 years when compared to ER-poor tumors. With longer follow-up, however, this initial advantage disappears primarily due to late recurrences. Her2 & Response to Therapy The HER2 gene encodes for a transmembrane glycoprotein that belongs to the epidermal growth factor receptor (EGFR) family of receptors, which play a key role in signal transduction controlling growth, differentiation, and possibly angiogenesis. Overexpression of the glycoprotein and/or amplification of its encoding gene is noted in 18–20% of breast cancer patients. HER2 overexpression/amplification is associated with an increased risk of recurrence and breast cancer death in the absence of systemic/targeted therapy and is also associated with resistance to endocrine therapy. However, HER2 overexpression/overamplification helps identify patients who benefit from the addition of agents that target the protein such as trastuzumab, a humanized monoclonal mouse antibody that binds the HER2 protein, and lapatinib, an oral tyrosine kinase inhibitor that blocks HER2. Curative Treatment All oncologic treatment may be classified as curative or palliative. Curative treatment intent is advised for early-stage and locally advanced disease (clinical stages I to IIIC disease). Treatment intent is palliative for patients with stage IV disease and for previously treated patients who develop distant metastases or unresectable local recurrence. Therapeutic Options RADICAL MASTECTOMY Historically, Halsted is credited with performing the first modern radical mastectomy in 1882 in the United States. This surgical procedure was the en bloc removal of the breast, pectoral muscles, and axillary lymph nodes. It was the standard surgical procedure performed for breast cancer in the United States from the turn of the 20th century until the 1950s. During the 1950s, emerging information about lymph node drainage patterns prompted surgeons to undertake the extended radical mastectomy, which is a radical mastectomy and the removal of the internal mammary lymph nodes. It was postulated that a more extensive dissection of the draining lymphatics would improve control rates and translate into improved survival. A randomized trial, however, proved no benefit to the extended radical mastectomy versus the radical mastectomy, and the former was abandoned. MODIFIED RADICAL MASTECTOMY Replacing radical mastectomy, the modified radical mastectomy (MRM) is the removal of the breast and underlying pectoralis major fascia, but not the muscle, and evaluation of selected axillary lymph nodes. Variations of this procedure include sacrificing the pectoralis minor muscle or not, and retracting, splitting, or transecting the pectoralis major to access the apex of the axilla for dissection. Because it is less invasive and less disfiguring, MRM provides a better cosmetic and functional result than radical mastectomy. Two prospective randomized trials, single-institution data, and several retrospective studies all demonstrate no difference in disease-free or overall survival rates between radical mastectomy and MRM for early-stage breast cancer. BREAST-CONSERVATION THERAPY BCT involves a surgical procedure such as a lumpectomy—an excision of the tumor mass with a negative surgical margin—an axillary evaluation, and postoperative irradiation. Several other operations, more limited in the scope of surgical dissection than MRM, such as segmental mastectomy, partial mastectomy, and quadrantectomy, are also used in conjunction with radiation and are part of the surgical component of BCT. Choice of Local Therapy Breast cancer is a multidisciplinary disease in which surgeons, medical and radiation oncologists, radiologists, pathologists, nurses, and psychosocial support staff all play fundamental roles. Working with the patient, this team recommends the most appropriate treatment strategy. Clinical and pathologic stage, as well as biologic aggressiveness, are the principal determinants guiding local therapy, treatment strategy, and, ultimately, outcome. For early-stage breast cancer, including node-positive cases, much of the decision for initial local therapy rests with the patient. MRM is always a valid choice for addressing the local treatment of breast cancer. Perhaps most importantly, the patient must be motivated and desire to maintain her breast in the face of a cancer diagnosis. This may entail some degree of physical, emotional, and psychological distress. For example, a patient may have to endure multiple re-excisions to obtain a negative surgical margin on the lumpectomy specimen. A patient may also experience resistance to BCT in areas where it is not commonly offered and where a multidisciplinary approach to breast cancer is not practiced. Because the treatment options for locally advanced and inflammatory breast cancers are in some ways less flexible than those for early-stage breast cancer, it is even more critical to engage the patient in the decision-making process for the choice of initial therapy. Mastectomy For about three-quarters of a century, radical mastectomy was considered standard therapy for breast cancer. The procedure was designed to remove the primary lesion, the breast in which it arose, the underlying muscle, and, by dissection in continuity, the axillary lymph nodes, which are most often the first site of regional spread beyond the breast. When radical mastectomy was introduced by Halsted, the average patient presented for treatment with locally advanced disease, and a relatively extensive procedure was often necessary just to remove all gross cancer. This is no longer the case. Patients now present with much smaller, less locally advanced lesions. In many cases, adjuvant therapy after MRM (eg, radiation) can even further reduce the incidence of local recurrence in certain patients with unfavorable tumor characteristics. In addition, 3 recent randomized trials of postmastectomy radiation, which confirmed a local control advantage, demonstrated an overall survival benefit in certain subsets of both pre- and postmenopausal women. For patients with ≥4 positive lymph nodes or large tumors ≥5 cm in diameter, postmastectomy radiation is strongly recommended. Breast-Conservation Therapy Because studies comparing radical mastectomy and MRM demonstrated no decrement in local control or survival, radical mastectomy has given way to MRM. In the 1980s, 6 prospective randomized trials were conducted worldwide that showed no significant difference in locoregional relapse or overall survival between breast-conserving surgery and radiation versus MRM for early-stage invasive breast cancer. In addition, an overview analysis showed equivalent survival with BCT as compared to mastectomy. There are a few absolute contraindications to BCT, which are mainly related to increased rates of in-breast recurrences or preclusion of use of radiation. These include persistently positive surgical margins, multicentric disease present in more than 1 quadrant of the breast, diffuse malignant-appearing calcifications throughout the breast precluding adequate resection, history of prior radiation therapy to the breast, and pregnancy. Unfortunately, no subgroup of patient with breast cancer undergoing breast conservation has a low enough risk of recurrence to justify the elimination of adjuvant therapy. Axillary Evaluation It is important to recognize that axillary evaluation is valuable both in planning therapy and in staging of the cancer. Axillary lymph node dissection has long been the mainstay for axillary staging in the treatment of patients with breast cancer. Although the removal of even occult cancer in axillary lymph nodes generally does not translate into an improvement in overall survival rates, regional failures will be lower. Axillary lymph node dissection is generally safe but may result in nerve damage and lymphedema, especially in patients receiving postoperative radiotherapy. Because of the potential for major morbidity associated with the procedure and questions regarding any survival advantage it would offer, some investigators examined the use of sentinel lymph node biopsy (SLNB) as an alternative to formal axillary dissection for the pathologic assessment of the clinically negative axilla. This procedure uses a tracer material that is injected into the tumor bed to map the tumor drainage to the primary or “sentinel” axillary lymph node(s). Adjuvant Systemic Therapy Hormonal Therapy Adjuvant hormonal therapy or manipulation is recommended for all women whose breast cancer expresses hormone receptors. Even if the tumor does not express estrogen hormone receptor protein but only progesterone, hormonal therapy may be beneficial. This recommendation is made regardless of age, menopausal status, involvement or number of positive lymph nodes, or tumor size. Until recently, 5 years of tamoxifen was considered to be the adjuvant hormonal therapy regimen of choice and remains a valuable option for both premenopausal and postmenopausal women with ER-positive tumors. Randomized trials support the 5-year duration, which is superior to shorter courses and does not expose the patient to the increased risk of adverse effects associated with longer use. Furthermore, use longer than 5 years does not appear to enhance the long-term benefit seen with just 5 years of use. More recently, aromatase inhibitors (AI) such as anastrozole have been shown to be as effective if not more effective than tamoxifen in postmenopausal women with early-stage, invasive breast cancer. In fact, in at least 2 large trials, anastrozole and letrozole were found to be superior to tamoxifen in terms of disease-free survival, time to recurrence, and the incidence of contralateral breast cancer, although no significant difference in overall survival was seen. The toxicity profile of AIs is also different, making them useful for women who would like to avoid the tamoxifen-related side effects. Compared to tamoxifen, the use of AIs confers a smaller risk of endometrial cancer, venous thromboembolic events, and hot flashes. However, AIs are associated with a higher risk of musculoskeletal disorders, osteoporosis, and cardiac events when compared to tamoxifen. Chemotherapy Cytotoxic chemotherapy is commonly offered to women as adjuvant treatment for both early-stage and locally advanced breast cancer. The goal of adjuvant chemotherapy is to eliminate occult microscopic metastases that are often responsible for late recurrences. Cytotoxic chemotherapy offers benefits to the many early and the majority of locally advanced breast cancer patients, although the magnitude of benefit is more pronounced in premenopausal and node-positive patients. The benefit of adding chemotherapy to endocrine therapy for patients with ER-positive tumors is more controversial, especially for patients with negative lymph nodes. The Oncotype DX 21-gene recurrence score assay is a potentially useful tool that could help predict patients with node-negative ER-positive tumors who have the lowest risk of distant recurrence, enough to justify elimination of chemotherapy. Polychemotherapy (≥2 agents) is superior to single-agent chemotherapy. Duration for 3–6 months or 4–6 cycles appears to offer optimal benefit without subjecting the patient to undue toxicity associated with more prolonged treatment, which adds little benefit in terms of overall outcome Several areas concerning chemotherapy have generated considerable interest but lack conclusive evidence. For instance, high-dose chemotherapy with bone marrow or stem cell rescue is not recommended. There is no evidence that high-dose regimens are superior to standard-dose polychemotherapy. Stem cell support or bone marrow transplant should be offered only on protocol. Follow-Up Care After primary treatment, breast cancer patients should be followed for life because of the long, insidious natural history of breast cancer. The goals of close breast cancer follow-up are to detect recurrences and second primaries after treatment in the ipsilateral breast and to detect new cancers in the contralateral breast. The risk of a second primary in the contralateral breast of a patient with a history of breast cancer is believed to be roughly 0.5–1% per year. Although there are no universally accepted guidelines, several consensus conferences have met to establish recommendations. After the completion of treatment, it is recommended that the patient undergo a physical examination every 4 months for the first 2 years, then every 6 months until year 5, and annually thereafter. A mammogram should be obtained annually for all patients and no less than 6 months after the completion of radiation therapy. Local Recurrence The development of local recurrence correlates with stage and thus tumor size as well as the presence and number of positive axillary lymph nodes, margin status, nuclear grade, and histologic type. The median time to recurrence is roughly 4 years, with a 1–2% risk per year for the first 5 years and a 1% risk per year thereafter. The treatment of local recurrences depends on the initial local therapy. In the breast, failures after BCT can be treated with salvage mastectomy with salvage rates of approximately 50%. In general, there is no difference in overall survival for an isolated breast recurrence successfully treated with salvage mastectomy. Node failures are more ominous. Edema of the Arm Lymphedema of the arm is a significant and often dreaded complication of breast cancer treatment. Lymphedema occurs as a result of lymphatic disruption and insult caused primarily by local treatment modalities like surgery and radiation. Although each of these modalities carries its own risk with respect to arm edema, a combined-modality approach further increases this risk. With a typical level I/II axillary lymph node dissection and radiation, the risk of lymphedema is roughly <10%. Breast Reconstruction Breast reconstruction, with the implantation of a prosthesis or autologous tissue such as transverse rectus abdominis myocutaneous flap (TRAM), is now commonly offered following mastectomy and can be very frequently performed immediately after surgery. Therefore, reconstruction should be discussed with patients prior to mastectomy and is not an obstacle to the diagnosis of recurrent cancer. Prognosis The stage of breast cancer is the single most reliable indicator of prognosis. Patients with disease localized to the breast and no evidence of regional spread after microscopic examination of the lymph nodes have by far the most favorable prognosis. ERs and PRs appear to be an important prognostic variable because patients with hormone receptor–negative tumors and no evidence of metastases to the axillary lymph nodes have a much higher recurrence rate than do patients with hormone receptor–positive tumors and no regional metastases. The histologic subtype of breast cancer (eg, medullary, lobular, comedo) seems to have little significance in prognosis once these tumors are truly invasive. Many patients who develop breast cancer will ultimately die of breast cancer. The mortality rate of breast cancer patients exceeds that of age-matched normal controls for nearly 20 years. Thereafter, the mortality rates are equal, although deaths that occur among the breast cancer patients are often directly the result of tumor. Five-year statistics do not accurately reflect the final outcome of therapy. When cancer is localized to the breast, with no evidence of regional spread after pathologic examination, the clinical cure rate with most accepted methods of therapy is 75–80%. Exceptions to this may be related to the hormonal receptor content of the tumor, tumor size, host resistance, or associated illness. Patients with small ER- and PR-positive tumors and no evidence of axillary spread probably have a 5-year survival rate of nearly 90%. Palliative Treatment of Recurrent and Metastatic Breast Cancer This section discusses palliative therapy of disseminated disease incurable by surgery (stage IV). Local Therapy Patients with metastatic breast cancer are unlikely to be cured of their disease, and for many, the goals of care shift from cure to palliation, symptom control, and improved quality of life. In general, local therapy, such as palliative radiotherapy or surgery when technically feasible, should be reserved for patients in order to control their symptoms and minimize the risk of complications. As part of multimodality treatment, surgery for patients with metastatic breast cancer should be reserved for patients with a good performance status, minimal organ involvement, prolonged disease-free interval, or indolent disease growth when the likelihood of achieving complete resection of the tumor or metastasis is reasonable. Hormonal Therapy Disseminated disease may respond to prolonged endocrine therapy such as ovarian ablation or administration of drugs that block hormone receptor sites or that block hormone synthesis or production. Hormonal manipulation is usually more successful in postmenopausal women. A favorable response to hormonal manipulation occurs in abo